Direxion S&P Biotech Bull 3X

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Apellis Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 268.3 M (forecast USD 203.29 M), actual EPS USD 0.1461 (forecast USD -0.3526)

Revolution Medicines released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 0 (forecast USD 2.425 M), actual EPS USD -2.2908 (forecast USD -1.8344)

Revolution Medicines Submits NDA for Daraxonrasib

Revolution Medicines reports Q1 operating loss of $445.222 million

TG Therap released FY2026 Q1 earnings on May 6 During-Market (EST), actual revenue USD 204.92 M (forecast USD 201.21 M), actual EPS USD 0.1199 (forecast USD 0.2719)

Revolution Medicines Exec Exercised Stock Options and Sold Shares

Revolution Medicines to release FY2026 Q1 earnings on May 6 After-Market EST, forecast revenue USD 2.425 M, EPS USD -1.8392

TG Therap to Release FY2026 Q1 Earnings on May 6 During Market Hours (EST), Forecast Revenue USD 200.92 M, EPS USD 0.2719

Revolution Medicines Sues Erasca for Patent Infringement, Stock Rises

Mizuho Maintains Buy Rating on Revolution Medicines, Targeting $185

Revolution Medicines Releases RM-055 Preclinical Data

Revolution Medicines Publishes Clinical Data for Daraxonrasib in Treating Pancreatic Cancer

Revolution Medicines issues $250 million convertible senior notes

Revolution Medicines' daraxonrasib shows positive results in pancreatic cancer phase III trial

Biogen plans to acquire Apellis

Tema Etfs LLC Reduced Holdings in Revolution Medicines, Inc.

Biogen to acquire Apellis Pharmaceuticals for $41 per share

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

ETON

SBIO

ARKG

IBBQ

LABU

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

TradingView

Eton Pharmaceuticals

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

OCGN

Ocugen Inc. (OCGN) shares fell 2.99% to $1.30 on Tuesday, marking the fourth consecutive day of losses. The stock is now 52.29% below its 52-week high of $2.73 reached on March 17. The broader market also declined, with the S&P 500 down 0.67% and the Dow Jones down 0.65%. Trading volume was 5.5 million, below the 50-day average of 9.4 million.

MarketWatch Automated

Ocugen

S&P 500

Dow Jones Industrial Average

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

DVAX

VXRT

Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-19 trial. The trial is fully enrolled with 5,400 participants, and results are expected in early 2027. The company reported a strong financial position with $61M cash, ensuring funding into Q2 2027. Actions taken to extend runway include restoring BARDA funding and a strategic partnership with Dynavax.

Dynavax Tech

Vaxart

Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027

CRBP

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 8.04% to $9.15 on Tuesday, marking the fourth consecutive day of losses. The stock is now 55.50% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals Inc. and Fortress Biotech Inc. had mixed performances, with Vanda down 1.48% and Fortress up 2.02%. Overall, the NASDAQ Composite Index dropped 0.84%.

Corbus Pharma

NASDAQ Composite Index

Vanda Pharma

Fortress Biotech

Viking Therap

Fortress Biotech Pref Share FBIOP 9.375 15/12/22

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

Charles River Laboratories International Inc. (CRL) shares rose 1.67% to $152.43, breaking a four-day losing streak, despite a poor overall market day. The S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. CRL's stock remains 33.40% below its 52-week high of $228.88. Competitors had mixed results, with Labcorp down 0.74% and Alnylam Pharmaceuticals and Bio-Techne rising 2.81% and 2.34%, respectively.

Charles River Laboratorie

iShares Genomics Immunology and Healthcare ETF

Labcorp

Alnylam Pharma

Bio-Techne

Factset Research

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

ADAG

Adagene's Chief Strategy Officer, Mickael Chane-Du, discussed the company's clinical strategy for its lead antibody program, ADG126, focusing on improving CTLA-4 inhibition. ADG126, a masked anti-CTLA-4 antibody, aims to enhance therapeutic efficacy in colorectal cancer, particularly in microsatellite-stable patients without liver metastases. The company is conducting a randomized Phase 2 trial to evaluate ADG126's effectiveness in combination with pembrolizumab, with results expected to guide future trials.

Market Beat

Adagene

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

CELC

LABD

Delphi Diagnostics has appointed Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Lindquist, an experienced oncology and life sciences executive, will lead the financial strategy as the company advances its Endocrine Activity Index® test for breast cancer treatment. His previous roles include CEO of InnoSIGN and Chief Business Officer at Celcuity. Lindquist's expertise is expected to drive growth and enhance personalized treatment options in breast cancer diagnostics.

prnewswire

Celcuity

iShares US Medical Devices

Direxion S&P Biotech Bear 3X

Natera

Roche

ROCHE HOLDINGS AG

17:05 ETDelphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer

GOVX

GOVXW

GeoVax Labs has priced a USD 3 million private placement, selling 2,027,027 common shares at-the-market under Nasdaq rules. The deal includes Series A and B warrants, both with a USD 1.48 exercise price. Closing is expected around May 19, 2026, with proceeds designated for working capital and corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent.

PUBT

GeoVax Labs

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

GeoVax prices USD 3 million private placement at-the-market under Nasdaq rules

REGN

Parabilis Medicines has filed for an IPO on the Nasdaq under the ticker 'PBLS'. The funds will support the late-stage development of its lead drug, zolucatetide, aimed at treating various cancers. The company focuses on developing Helicons, peptides targeting undruggable proteins, and has strategic partnerships, including one with Regeneron. Currently, Parabilis is pre-revenue, with significant operational losses reported for 2025.

Regeneron Pharma

Johnson & Johnson

Merck

Theravance BioPharma

Blueprint Med

Agios Pharmac

Seres Therap

Parabilis Medicines, Clinical-Stage Biopharma Targeting Undruggable Proteins, Files for Nasdaq IPO

CING

Cingulate announced that Class II directors Jeff Ervin and Jay Roberts will not seek re-election at the 2026 annual meeting as part of a plan to reduce the board size to five directors. Jeff Hargroves has been moved to the Class II slate after resigning as a Class I director. Peter Werth and Frederick Jiang remain as Class I directors.

Cingulate

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM)

Cingulate says directors Ervin, Roberts won’t seek re-election at 2026 annual meeting

MGRX

Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls.

Mangoceuticals

iShares US Healthcare Providers

SPDR S&P Health

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

Direxion S&P Biotech Bull 3X(LABU.US)